Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Division of Pathology and Laboratory Medicine, Department of Anatomic Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Cytopathol. 2020 Sep;128(9):629-636. doi: 10.1002/cncy.22313.
Biomarker testing in patients with advanced stage non-small cell lung cancer provides essential information that can be used to select the most appropriate therapy. The regular updates of guideline recommendations reflect the growing number of biomarkers that must be assessed, and as such signal the shift from single-gene assays to more comprehensive genomic profiling using next-generation sequencing modalities. Cytology and small biopsy specimens have proven to be more than adequate substrates for these types of ancillary molecular testing; however, other alternative testing substrates are beginning to emerge. These include so-called liquid biopsies as well the supernatant fluid from cytology specimens, both of which have demonstrated promise for use in the clinical realm. This review will briefly cover the current state of non-small cell lung cancer biomarker testing in the United States, with a focus on these novel nonconventional substrates that are increasingly being incorporated into testing paradigms.
在晚期非小细胞肺癌患者中进行生物标志物检测可提供重要信息，有助于选择最合适的治疗方法。指南推荐的定期更新反映了必须评估的生物标志物数量不断增加，这也标志着从单一基因检测向使用下一代测序方法进行更全面的基因组分析的转变。细胞学和小活检标本已被证明是这些辅助分子检测的足够理想的基质；然而，其他替代检测基质也开始出现。这些包括所谓的液体活检以及细胞学标本的上清液，两者都已证明在临床应用中有一定的前景。本文将简要介绍美国目前非小细胞肺癌生物标志物检测的现状，重点介绍这些正在逐渐纳入检测模式的新型非传统基质。
